VentaProst in Subjects With COVID-19 Requiring Mechanical Ventilation

• Status: Completed
• Trial end date: 2021-06-29
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to investigate whether inhaled epoprostenol given via a breath actuated delivery system will help improve oxygen levels and treatment outcomes in patients with COVID-19 who are on mechanical ventilation.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Aerogen Pharma Limited
• Collaborator: Ohio State University
• Treatments: Epoprostenol; Tezosentan

Criteria

Inclusion Criteria:

• Confirmed COVID-19 positive by RT-PCR test

• Patients who require invasive mechanical ventilation.

• Consent or professional consent obtained

Exclusion Criteria:

• Patients on ECMO support.

• Patients receiving another inhalation research medication or inhaled nitric oxide.

• Not expected to survive for 48 hours.

• Allergy to Epoprostenol and its diluent